As The Deep Dive reported on late yesterday afternoon, Tetra Bio Pharma (TSXV: TBP) has received approval from Health Canada for over the counter products. The catch, is that the company has actually received approval for two separate products from the regulator. Both products are to be marketed under the Terpacan banner.
The products, referred to as Terpacan (hemorrhoids) and Terpacan (back & muscle pain) are expected to be arriving on Canadian pharmacy shelves by mid-2020. The company is currently in the process of finalizing supply, sales, and distribution agreements with “several companies.”
Tetra Bio Pharma also anticipates on acquiring sales in international jurisdictions within 2020, which includes both the United States and Europe. Terpacan is currently waiting on final marketing approval in these regions, however they are expected to be acquired in the near term. The company currently anticipates a late year launch in the United States, where it is in the process of finalizing a manufacturing agreement.
Tetra Bio Pharma last traded at $0.56 on the TSX Venture.
Information for this briefing was found via Sedar, Health Canada and Tetra Bio-Pharma. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
